JCT  Vol.5 No.2 , February 2014
Investigation of Combining Serum Tumor Biomarkers and Clinical Features for Elderly Lung Cancer Diagnosis and Classification
ABSTRACT

To evaluate the diagnosis model of serum tumor biomarker and several clinical features diagnose and classification for lung cancer, the solid protein chip technology (C-12) was used to detect the biomarkers of SF, CEA, CA242, NSE, CA125, CA19-9 and CA15-3 in serum and several clinical features of tumors and benign disease in elderly lung cancer patients were collected. Set up a discriminating analysis as a function diagnostic model in clinical elderly lung cancer diagnosis and sub-type discrimination. In combination of 2 obvious clinical indicators and 2 serum markers, it is possible to provide a diagnosis tool for lung cancer. With the help of mathematic model, it is promising to reduce the misjudgment risk based on the previous experience and therefore establish a reliable diagnosing function. This model is simple, cost-effective and easy to adapt in practice, and can also be used in screening of large population.


Cite this paper
Y. Tian, M. Yu, L. Sun, X. Ren, W. Liang, W. Shang, S. Huo, L. Liu, Y. Ren, H. Wen, Z. Yang, S. Wei and C. Wang, "Investigation of Combining Serum Tumor Biomarkers and Clinical Features for Elderly Lung Cancer Diagnosis and Classification," Journal of Cancer Therapy, Vol. 5 No. 2, 2014, pp. 133-140. doi: 10.4236/jct.2014.52016.
References
[1]   H. H. Lin, M. Murray, T. Cohen, et al., “Effects of Smoking and Solid-Fuel Use on COPD, Lung Cancer, and Tuberculosis in China: A Time-Based, Multiple Risk Factors, Modeling Study,” Lancet, Vol. 372, No. 9648, 2008, 1473-1483.

[2]   H. M. Zeng, R. S. Zheng, S. W. Zhang, et al., “Trend Analysis of Cancer Mortality in China between 1989 and 2008,” Chinese Journal of Clinical Oncology, Vol. 7, No. 34, 2012, pp. 525-531.

[3]   W. Q. Chen, R. S. Zheng, H. M. Zeng, et al., “Trend Analysis and Projection of Cancer Incidence in China between 1989 and 2008,” Chinese Journal of Clinical Oncology, Vol. 7, No. 34, 2012, pp. 517-524.

[4]   T. S. Mok, Y. L. Wu, S. Thongprasert, et al., “Gefitinb or Carboplatin Paclitaxel in Pulmonary Adenocarcinoma,” The New England Journal of Medicine, Vol. 361, No. 10, 2009, p. 947.
http://dx.doi.org/10.1056/NEJMoa0810699

[5]   Y. Bang, E. L. Kwak, A. Shaw, et al., “Clinical Activity of the Oral ALK Inhibitor, PF-02341066, in ALK-Positive Patients with Non-Small Cell Lung Cancer,” Journal of Clinical Oncology, Vol. 28, No, 18, 2010, p. 3.

[6]   G. V. Scagliotti, P. Parikh, J. Von Pawel, et al., “Phase Ⅲ Study Comparing Cisplatin plus Gemcitabine with Cisplatin plus Pemetrexed in Chemotherapy-Naive Patients with Advanced-Stage Non-Small-Cell Lung Cancer,” Chinese Journal of Clinical Oncology, Vol. 26, No. 21, 2008, p. 3543.
http://dx.doi.org/10.1200/JCO.2007.15.0375

[7]   A. Jemal, M. J. Thun, T. L. Rise, et al., “Annual Report to the Nation on the Status of Cancer, 1975-2005, Featuring Trends in Lung Cancer, Tobacco Use, and Tobacco Control,” Journal of the National Cancer Institute, Vol. 100, No. 23, 2008, pp.1672-1694. http://dx.doi.org/10.1093/jnci/djn389

[8]   J. A. Alberg, J. G. Ford and J. M. Samet, “Epidemiology of Lung Cancer,” Chest, Vol. 132, Suppl. 3, 2007, pp. 29-55. http://dx.doi.org/10.1378/chest.07-1347

[9]   I. Visintin, Z. Feng, G. Longton, et al., “Diagnostic Markers for Early Detection of Ovarian Cancer,” Clinical Cancer Research, Vol.14, 2008, pp. 1065-1072. http://dx.doi.org/10.1158/1078-0432.CCR-07-1569

[10]   J. Zhou, L. Yu, X. Gao, et al., “Plasma MicroRNA Panel to Diagnose Hepatitis B Virus-Related Hepatocellular Carcinoma,” Journal of Clinical Oncology, Vol. 38, 2011, p. 2697.

[11]   I. Visintin, Z. D. Feng, G. Longton, et al., “Diagnostic Markers for Early Detection of Ovarian Cancer,” Clinical Cancer Research, Vol. 14, No. 4, 2008, pp. 1065-1072. http://dx.doi.org/10.1158/1078-0432. CCR-07-1569

[12]   M. Fiorentino, E. Capizzi and M. Loda, “Blood and Tissue Biomarkers in Prostate Cancer: State of the Art,” Urologic Clinics of North America, Vol. 37, No. 1, 2010, pp. 131-141. http://dx.doi.org/10.1016/ j.ucl.2009.11.006

[13]   NCCN Guidelines for Patients, 2012. Http://www.nccn.com

[14]   T. R. Asmis, K. Ding, L. Seymour, et al., “Age and Comorbidity as Independent Prognostic Factors in the Treatment of Non-Small-Cell Lung Cancer: A Review of National Cancer Institute of Canada Clinical Trials Group Trial,” Journal of Clinical Oncology, Vol. 26, No. 1, 2008, pp. 54-59.
http://dx.doi.org/10.1200/JCO.2007.12.8322

[15]   M. Okada, W. Nishio, T. Skaamoto, et al., “Effect of Histologic Type and Smoking Status on Interpretation of Serum Carcinoembryonic Antigen Value in Non-Small Cell Lung Carcinoma,” The Annals of Thoracic Surgery, Vol. 78, No. 3, 2004, p. 1004. http://dx.doi.org/10.1016/j.athoracsur. 2004.03.019

[16]   M. Tomita, Y. Matsuzaki, M. Ham, et al., “Relationship between Serum Carcinoembryoinc Antigen Level and T Status in Non-Small Cell Lung Cancer,” Anticancer Research, Vol. 5B, 2006, p. 845.

[17]   R. Kawachi, Y. Kazato, H. Kei, et al., “Clinical Significance of Preoperative Carcincembryonic Antigen Level for Clinical Stage I Non-Small Cell Lung Cancer: Can Preoperative Carcinoembryonic Antigen Level Predict Pathological Stage?” Interactive Cardio Vasc Thoracic Surgery, Vol. 9, No. 2, 2009, p. 199.

[18]   K. Hotta, K. Kiura, M. Tabata, et al., “Role of Early Serial Change in Serum Carcinoembryonic Antigen Levels as a Predictive Marker for Radiological Response to Gefitinib in Japanese Patients with Non-Small Cell Lung Cancer,” Anticancer Research, Vol. 27, No, 3B, 2007, p. 1737.

[19]   C. H. Chiu, Y. N. Shih, S. M. Tsai, et al., “Serum Carcinoembryonic Antigen as a Predictive Marker for Sensitivity to Gefitinib in Advanced Non-Small Cell Lung Cancer,” Lung Cancer, Vol. 57, No. 2, 2007, p. 213. http://dx.doi.org/10.1016/j.lungcan.2007.02.016

[20]   H. J. Sung and J. Y. Cho, “Biomarkers for the Lung Cancer Diagnosis and Their Advances in Proteomics,” BMB Reports, Vol. 41, No. 9, 2008, pp. 615-625. http://dx.doi.org/10.5483/BMBRep. 2008.41.9.615

[21]   S. R. Weinberger, E. A. Damasso and E. T. Fung, “Current Achievements Using Protein Chip Array Technology,” Current Opinion in Chemical Biology, Vol. 6, No. 1, 2002, pp. 86-91.
http://dx.doi.org/10.1016/S1367-5931(01)00282-4

[22]   M. R. Spitz, W. K. Hong, C. H. Amos, et al., “A risk Model for Prediction of Lung Cancer,” Journal of the National Cancer Institute, Vol. 99, No. 7, 2007, pp. 15-726. http://dx.doi.org/10.1093/jnci/djk153

[23]   S. Cedres, I. Nunez, M. Longo, et al., “Serum Tumor Markers CEA, CYFRA21-1, and CA-125 Are Associated With Worse Prognosis In Advanced Non-Small-Cell Lung Cancer (NSCLC),” Clinical Lung Cancer, Vol. 3, No. 12, 2011, pp. 172-179. http://dx.doi.org/10.1016/j.cllc.2011.03.019

[24]   S. Holdenrieder, J. Pawel, E. Dankelmann, et al., “Nucleosomes, ProGRP, NSE, CYFRA21-1, and CEA in Monitoring First-Line Chemotherapy of Small Cell Lung Cancer,” Clinical Cancer Research, Vol. 14, 2008, pp. 7813-7821. http://dx.doi.org/10.1158/1078-0432.CCR-08-0678

[25]   N. Kosaka, H. Iguchi and T. Ochiya, “Circulating microRNA in Body Fluid: A New Potential Biomarker for Cancer Diagnosis and Prognosis,” Cancer Science, Vol. 101, No. 10, 2010, pp. 2087-2092. http://dx.doi.org/10.1111/j.1349-7006.2010.01650.x

[26]   M. F. Akay, “Support Vector Machines Combined with Feature Selection for Breast Cancer Diagnosis,” Expert Systems with Applications, Vol. 2, No. 36, 2009, pp. 3240-3247. http://dx.doi.org/10.1016/ j.eswa.2008.01.009

[27]   E. F. PatzJr, M. J. Campa, E. B. Gottlin, et al., “Panel of Serum Biomarkers for the Diagnosis of Lung Cancer,” Journal of Clinical Oncology, Vol. 25, No. 35, 2007, pp. 5578-5583. http://dx.doi.org/10. 1200/JCO.2007.13.5392

 
 
Top